BCL9L and melanoma: Indeed, we confirmed that the expression of BCL9L was remarkably upregulated in soft breast (4T1 and MCF‐7) and melanoma (B16 and MP‐1) tumor cells, as evidenced by qPCR, Western blot, and immunostaining (Figs 5A, and EV5A and B).